Stockreport

Kura Oncology: Poised For A Lift With Combinations [Seeking Alpha]

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF Ziftomenib's initial single-agent results are modest, but combination regimens (notably KOMET-007) show high response rates and deep remissions. KURA is well capitali [Read more]